Uses
Rubone, a chalcone analog, is a modulator of miR-34a. Rubone upregulates miR-34a expression in a p53 dependent manner, downregulates the downstream target Bcl-2 and Cyclin D1 expression, and suppresses hepatocellular carcinoma (HCC) growth in vivo. Rubone enhances the anticancer effect of Paclitaxel (PTX; HY-B0015) in PTX-resistant prostate cancer cell lines by reversing the expression of miR-34a downstream targets[1][2][3].
Definition
ChEBI: Rubone is a member of chalcones.
Biological Activity
Rubone has strong anticancer activity. Rubone and paclitaxel (PTX) combination therapy retarded cancer cell growth, migration and cancer stem-like cells (CSC) population growth.', 'Rubone is a miR34a modulator th at specifically restores miR34a in hepatocellular carcinoma cells with wild-type or mutated p53. Rubone potently inhibits growth of hepatocellular carcinoma in a mouse xenograft model. Rubone does not effect the growth of nontumorigenic human hepatocytes.', 'Rubone is a miR34a modulator th at specifically restores miR34a in hepatocellular carcinoma cells.
in vivo
Rubone monotherapy (20 mg/kg loaded PEG-PCD micelles; iv for five doses every other day) or combination therapy with PTX (10 mg/kg for each drug loaded PEG-PCD micelles) significantly upregulates miR-34a expression in tumor. The combination therapy inhibits tumor growth. Rubone monotherapy failed to suppress tumor cell proliferation[3].
| Animal Model: | 8 weeks old male nude mice transfected prostate cancer cells[3] |
| Dosage: | 20 mg/kg or 10 mg/kg for each drug (PTX and Rubone) loaded PEG-PCD micelles |
| Administration: | Intravenously for five doses every other day |
| Result: | Had little effect on body weight loss and inhibited tumor growth.
Monotherapy or combination therapy with PTX significantly upregulated miR-34a expression in tumor.
Alone or with PTX significantly reversed E-cadherin, Cyclin D1, and SIRT1 expression.
|
References
[1] Zhangang Xiao, et al. Small molecule targeting miR-34a for cancer therapy. Mol Cell Oncol. 2015 Feb 24;2(1):e977160. DOI:
10.4161/23723556.2014.977160[2] Lu Zhang, et al. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res. 2019 Feb 4;38(1):53. DOI:
10.1186/s13046-019-1059-5[3] Di Wen, et al. Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer. Cancer Res. 2017 Jun 15;77(12):3244-3254. DOI:
10.1158/0008-5472.CAN-16-2355
